Staining pattern and intensity of CD10 expression in Urothelial carcinoma and its prognostic significanc

Abstract

Abstract Introduction: Urinary bladder cancer is common malignancy of the genitourinary tract in both males and females.CD10 is cell surface zinc dependent metalloprotease which may play a crucial role in tumor progression, invasion and metastasis. The present study was done to analyze staining pattern and intensity of CD10 and its association with grade, stage and prognosis of urothelial carcinoma. Materials and Methods: The prospective study included 51 cases of urothelial carcinoma over a period of one year which were followed up for three years. The staining pattern and intensity of CD10 immunostaining was correlated with histopathological grade, stage and survival of these patients. Results: The maximum number of urothelial carcinoma cases (33.3%) were in the age group of 60-70 years with mean age of 60.4 years. The staining pattern and intensity of CD10 showed statistical significant increase with increase of histopathological grade, stage of tumor and with decrease of survival of patients (p Conclusion: The study concludes that there is significant association between staining intensity and score of CD10 immuno-expression with histopathological grade, stage and the survival in patients of urothelial carcinoma.The staining intensity and pattern of CD10 immuno-expression may be helpful in determination of prognosis of urothelial carcinoma cases. In addition, it is suggested that further larger studies with extended follow ups may be done to evaluate the exact role of CD10 in prognosis of urothelial carcinoma. Keywords: Urothelial carcinoma, CD10, Histopathological grade, Stage, Survival, Prognosis. Introduction Urinary bladder cancer represents the common and frequent malignancy of the genitourinary tract in both males and females. Globally the incidence of bladder cancer is 3.1% with the mortality of about 2% and age standardized rate is of 5.3/100000 population.[1]In India the incidence of bladder cancer is 1.6% with the mortality o